Peptide to Inhibit CD200 for Oncology is under clinical development by OX2 Therapeutics and currently in Phase I for Recurrent Glioblastoma Multiforme (GBM). According to GlobalData, Phase I drugs for Recurrent Glioblastoma Multiforme (GBM) have an 87% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Peptide to Inhibit CD200 for Oncology’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Peptide to Inhibit CD200 for Oncology overview

Peptide is under development for the treatment of breast cancer, high grade glioma, diffuse midline glioma/diffuse intrinsic pontine glioma and recurrent glioblastoma. It acts by targeting CD200. It is administered through parenteral route.

OX2 Therapeutics overview

OX2 Therapeutics, Inc., is a healthcare therapeutics company that focuses on treating brain tumors. The company is headquartered in United States.

For a complete picture of Peptide to Inhibit CD200 for Oncology’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.